INTRAVESICAL INTERLEUKIN-2 IN T1 PAPILLARY BLADDER CARCINOMA: REGRESSION OF MARKER LESION IN 8 OF 10 PATIENTS
- 1 April 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 159 (4) , 1183-1186
- https://doi.org/10.1016/s0022-5347(01)63548-1
Abstract
Conclusions To our knowledge this report represents the first study of the effect of IL-2 on marker lesions left in place after transurethral resection. The results indicate that IL-2 instillations are feasible, and the combination of transurethral resection and IL-2 instillation may have a powerful antitumor effect. The therapeutic effects may not simply be due to intravesical IL-2, because previous transurethral resection probably caused some influx of infiltrating cells and the marker may have had tumor associated antigens. Consequently these effects may be due to the interaction of tumor associated antigens, infiltrating cells and IL-2.Keywords
This publication has 14 references indexed in Scilit:
- Optimal regimes for local IL-2 tumour therapyInternational Journal of Cancer, 1996
- Phase II trials in Ta, T1 bladder cancer. The marker tumour conceptBritish Journal of Urology, 1996
- INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES?International Journal of Urology, 1995
- A Phase I Study of Intravesical Continuous Perfusion of Recombinant Interleukin-2 in Patients with Superficial Bladder CancerAmerican Journal of Clinical Oncology, 1995
- Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-upCancer Immunology, Immunotherapy, 1995
- Local Immunotherapy of Superficial Bladder Cancer by Intravesical Instillation of Recombinant lnterleukin-2European Urology, 1995
- Marker tumour response to Evans and Pasteur bacilie Calmette‐Guérin in multiple recurrent pTa/pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)British Journal of Urology, 1994
- Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinomaVeterinary Immunology and Immunopathology, 1994
- Histological Parameters and Pitfalls in the Interpretation of Bladder Biopsies in Bacillus Calmette-Guerin Treatment of Superficial Bladder CancerJournal of Urology, 1986
- Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary reportInternational Journal of Cancer, 1984